A New Clinical Trial Design Combining Phases 2 and 3: Sequential Designs with Treatment Selection and a Change of Endpoint Susan ToddNigel Stallard Clinical and Nonclinical Drug Development 30 December 2005 Pages: 109 - 118
Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management Donald P. ReitbergSidney L. WeissEve del Rio Clinical and Nonclinical Drug Development 30 December 2005 Pages: 119 - 124
Choosing the Number of Doses and the Cohort Size for Phase 1 Dose-Escalation Studies Yinghui Zhou Statistics 30 December 2005 Pages: 125 - 137
Model-Based Correction to the QT Interval for Heart Rate for Assessing Mean QT Interval Change Due to Drug Effect Greg C. G. WeiJosh Y. H. Chen Statistics 30 December 2005 Pages: 139 - 148
The Expected Toxicity Rate at the Maximum Tolerated Dose in Bridging Studies in Alzheimer’s Disease Seung-Ho KangChul Ahn Statistics 30 December 2005 Pages: 149 - 157
Drug Information Obscured on Over-the-Counter Medication Labels by External Tags Sujit S. SansgiryLauro L. BixManjiri D. Pawaskar Drug Information 30 December 2005 Pages: 159 - 170
The Application of Metrics to Determine the Work Rate for Producing the First Draft of the Clinical Study Report: A Case Study Thomas J. Purcell Drug Information 30 December 2005 Pages: 171 - 175
Clinical Trial Capacity in East Africa: A Pilot Survey Ebi KimananiTimothy Johns Drug Regulation 30 December 2005 Pages: 177 - 184
Good Review Practices: The First Step Forward for the Korea Food and Drug Administration Howard Lee Drug Regulation 30 December 2005 Pages: 185 - 192
Recent Developments in European Pharmaceutical Law 2004: A Legal Point of View Markus HartmannFlorence Hartmann-Vareilles Drug Regulation 30 December 2005 Pages: 193 - 207
6th Middle East Regulatory Conference (MERC): Key Proceedings Brian HewittAfschin Khodaverdi-AfaghiOlivier Moreau Proceedings 30 December 2005 Pages: 209 - 214
